Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC

drugsApril 18, 2019

Tag: FDA , Merck , NSCLC , monotherapy , Keytruda

PharmaSources Customer Service